BR112016028755A2 - anticorpo ou fragmento de ligação ao antígeno macromolécula, molécula de ácido nucleico, composição farmacêutica, antígeno, e, métodos para fabricar um anticorpo e para selecionar um anticorpo. - Google Patents

anticorpo ou fragmento de ligação ao antígeno macromolécula, molécula de ácido nucleico, composição farmacêutica, antígeno, e, métodos para fabricar um anticorpo e para selecionar um anticorpo.

Info

Publication number
BR112016028755A2
BR112016028755A2 BR112016028755A BR112016028755A BR112016028755A2 BR 112016028755 A2 BR112016028755 A2 BR 112016028755A2 BR 112016028755 A BR112016028755 A BR 112016028755A BR 112016028755 A BR112016028755 A BR 112016028755A BR 112016028755 A2 BR112016028755 A2 BR 112016028755A2
Authority
BR
Brazil
Prior art keywords
antibody
sequence
antibodies
antigen
site
Prior art date
Application number
BR112016028755A
Other languages
English (en)
Other versions
BR112016028755B1 (pt
Inventor
Vanhove Bernard
Mary Caroline
Poirier Nicolas
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52434718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016028755(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of BR112016028755A2 publication Critical patent/BR112016028755A2/pt
Publication of BR112016028755B1 publication Critical patent/BR112016028755B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5418—IL-7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)

Abstract

a invenção refere-se a anticorpos direcionados contra cd127, a cadeia alfa do receptor de interleucina 7 (il-7) il-7r) e que têm propriedades antagonistaas para a interação il-7-il-7r, podem apresetnar atividade citotóxica contra células positivadas para cd127, mas não aumentam a maturação de células dendríticas (dcs) induzida por tslp, uma citocina que também usa cd127 como parte de seu receptor. alternativa ou adicionalmente, esses anticorpos não induzem a internalização de cd127 e/ou inibem a internalização induzida por il-7 de cd127. de acordo com outro aspecto da invenção, são fornecidos anticorpos que reconhecem um epítopo de cd127 humano que compreende sequências do sítio 2b de cd127, em particular o epítopo que compreende as sequências de cd127 humano do domínio d1 e do sítio 2b de cd127, em particular o epítopo compreende pelo menos uma sequência de d1 que compreende a seq id no: 115 (em particular que compreende a seq id no: 110 e/ou a seq id no: 111 e/ou uma sequência do sítio 2b que compreende a sequência de seq id no: 116 e, opcionalmente, também compreende a seq id no: 117 (em particular compreende a seq id no: 111). os anticorpos da invenção são adequados para uso a fim de medicar uma afecção diagnosticada em um paciente humano que resulta da patogênese relacionada à linfopoiese, quando as trajetórias de sinalização de il-7 fornecem contribuição para a dita patogênese, especialmente quando um aumento na maturação, mais precisamente a regulação crescente de moléculas coestimultórias, de células dendríticas é indesejável.
BR112016028755-0A 2014-06-10 2015-06-10 Anticorpo ou fragmento de ligação ao antígeno do mesmo,macromolécula, molécula de ácido nucleico, composição farmacêutica, uso de uma macromolécula, e, métodos para fabricar um anticorpo e para selecionar um anticorpo BR112016028755B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462010117P 2014-06-10 2014-06-10
US62/010117 2014-06-10
EP15305078.6 2015-01-23
EP15305078.6A EP2955196A1 (en) 2014-06-10 2015-01-23 Antibodies directed against CD127
PCT/EP2015/062993 WO2015189302A1 (en) 2014-06-10 2015-06-10 Antibodies directed against cd127

Publications (2)

Publication Number Publication Date
BR112016028755A2 true BR112016028755A2 (pt) 2017-11-14
BR112016028755B1 BR112016028755B1 (pt) 2024-01-16

Family

ID=52434718

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016028755-0A BR112016028755B1 (pt) 2014-06-10 2015-06-10 Anticorpo ou fragmento de ligação ao antígeno do mesmo,macromolécula, molécula de ácido nucleico, composição farmacêutica, uso de uma macromolécula, e, métodos para fabricar um anticorpo e para selecionar um anticorpo

Country Status (26)

Country Link
US (3) US10428152B2 (pt)
EP (2) EP2955196A1 (pt)
JP (2) JP7324565B2 (pt)
KR (1) KR102612930B1 (pt)
CN (1) CN106715471B (pt)
AP (1) AP2016009599A0 (pt)
AU (1) AU2015273532C1 (pt)
BR (1) BR112016028755B1 (pt)
CA (1) CA2950823A1 (pt)
CL (1) CL2016003172A1 (pt)
CR (1) CR20160576A (pt)
EA (1) EA039303B1 (pt)
HK (1) HK1231487A1 (pt)
IL (1) IL249449B (pt)
MA (1) MA40202A (pt)
MX (1) MX2016016236A (pt)
MY (1) MY190889A (pt)
NZ (1) NZ726932A (pt)
PE (1) PE20170324A1 (pt)
PH (1) PH12016502445A1 (pt)
RU (1) RU2734076C2 (pt)
SA (1) SA516380455B1 (pt)
SG (1) SG11201610036PA (pt)
TN (1) TN2016000528A1 (pt)
UA (1) UA125366C2 (pt)
WO (1) WO2015189302A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
CA3014313A1 (en) * 2016-02-29 2017-09-08 Ose Immunotherapeutics Non-antagonistic antibodies directed against the alpha chain of il7 receptor extracellular domain and use thereof in cancer treatment
WO2018104483A1 (en) 2016-12-09 2018-06-14 Ose Immunotherapeutics Antibodies and polypeptides directed against cd127
EP3676292A1 (en) * 2017-08-29 2020-07-08 OSE Immunotherapeutics Method and preparation for sorting out t effector cells using anti-cd127 antibodies for applications in cell therapy
CN110117325B (zh) * 2018-03-09 2023-06-20 重庆市畜牧科学院 一种猪cd127多肽及其编码基因和应用
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP2022538083A (ja) 2019-06-21 2022-08-31 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
WO2020254828A1 (en) 2019-06-21 2020-12-24 Vhsquared Limited Compositions
AU2020294980A1 (en) * 2019-06-21 2022-02-17 Sorriso Pharmaceuticals, Inc. Polypeptides
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
US20220389104A1 (en) 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
WO2023232826A1 (en) 2022-05-30 2023-12-07 Ose Immunotherapeutics Biomarkers of il7r modulator activity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2655392A1 (en) 2006-05-31 2007-12-06 The Regents Of The University Of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
PE20170687A1 (es) 2010-01-28 2017-06-13 Glaxo Group Ltd Proteinas de enlace a cd127
US8298535B2 (en) 2010-02-24 2012-10-30 Rinat Neuroscience Corp. Anti-IL-7 receptor antibodies
EP2583980A1 (en) 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
CA3014313A1 (en) 2016-02-29 2017-09-08 Ose Immunotherapeutics Non-antagonistic antibodies directed against the alpha chain of il7 receptor extracellular domain and use thereof in cancer treatment

Also Published As

Publication number Publication date
CN106715471A (zh) 2017-05-24
EA201692460A1 (ru) 2017-04-28
TN2016000528A1 (en) 2018-04-04
AU2015273532B2 (en) 2021-03-04
JP2017522903A (ja) 2017-08-17
HK1231487A1 (zh) 2017-12-22
US11440964B2 (en) 2022-09-13
EP2955196A1 (en) 2015-12-16
IL249449B (en) 2020-06-30
CN106715471B (zh) 2021-04-09
RU2016151265A (ru) 2018-07-18
AU2015273532C1 (en) 2021-07-15
SG11201610036PA (en) 2016-12-29
SA516380455B1 (ar) 2020-12-22
CL2016003172A1 (es) 2017-07-14
JP2021184731A (ja) 2021-12-09
MY190889A (en) 2022-05-17
UA125366C2 (uk) 2022-03-02
KR20170019417A (ko) 2017-02-21
CR20160576A (es) 2017-05-08
KR102612930B1 (ko) 2023-12-13
MA40202A (fr) 2017-04-19
CA2950823A1 (en) 2015-12-17
US20170129959A1 (en) 2017-05-11
US20230340133A1 (en) 2023-10-26
IL249449A0 (en) 2017-02-28
MX2016016236A (es) 2017-07-05
EP3155014A1 (en) 2017-04-19
AP2016009599A0 (en) 2016-11-30
WO2015189302A1 (en) 2015-12-17
US10428152B2 (en) 2019-10-01
RU2734076C2 (ru) 2020-10-12
BR112016028755B1 (pt) 2024-01-16
AU2015273532A1 (en) 2016-12-22
RU2016151265A3 (pt) 2019-02-08
EA039303B1 (ru) 2022-01-11
PH12016502445A1 (en) 2017-03-06
PE20170324A1 (es) 2017-04-01
NZ726932A (en) 2022-02-25
US20190382497A1 (en) 2019-12-19
JP7324565B2 (ja) 2023-08-10

Similar Documents

Publication Publication Date Title
BR112016028755A2 (pt) anticorpo ou fragmento de ligação ao antígeno macromolécula, molécula de ácido nucleico, composição farmacêutica, antígeno, e, métodos para fabricar um anticorpo e para selecionar um anticorpo.
EA201992131A1 (ru) Высокоаффинные специфичные к mage-a1 tcr и их применение
CY1122399T1 (el) Αγωνιστικοι παραγοντες δεσμευσης του υποδοχεα tnf
BR112018003535A2 (pt) receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão
EA201790953A1 (ru) Изменение экспрессии гена в cart-клетках и их применения
BR112018008442A2 (pt) receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
BR112013028779A2 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, método para tratar um paciente humano afligido com um distúrbio ou doença inflamatórios, e, uso de uma composição
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
BR112013018399A2 (pt) anticorpos anti-il1rap e seus usos para tratamento humano
BR112017003836A2 (pt) processo para sintetizar dna livre de células
BR112017005390A2 (pt) células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
BR112012030664A2 (pt) proteína de ligação de antígeno humanizada, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, métodos para a produção de uma proteína de ligação de antígeno, para tratar um indivíduo afligido com uma doença e para aumentar a massa muscular, aumentar a força muscular, e/ou melhorar a função muscular em um paciente, e, composição farmacêutica.
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
AR073072A1 (es) Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
BR112016001114A2 (pt) membros da família tnf direcionados modificados
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
AR080685A1 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
MX2019013690A (es) Conjugados de farmaco-proteina con ciclodextrina.
EA201691853A1 (ru) Агонисты мускариновых рецепторов
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/06/2015, OBSERVADAS AS CONDICOES LEGAIS